Aims: To analyse the effects of patient characteristics and different oral antidiabetes drug (OAD) use on standardised clinical outcomes in type 2 diabetes patients initiating insulin glargine 100 U/mL (Gla-100).
| INTRODUCTION
The number of people with diabetes has grown almost 4-fold in recent decades to an estimated 422 million in 2014, 1 due largely to type 2 diabetes (T2D), which is characterised by progressive insulin resistance, insulin deficiency, and defects in beta cell function. 2 Owing to the progressive nature of T2D, patients who are treated initially with oral antidiabetes drugs (OADs) may require initiation of basal insulin to maintain overall glucose control and to minimise the risk of developing diabetes-related complications. 3, 4 Present guidelines recommend intensification of therapy in patients inadequately controlled with current treatments, proposing basal insulin as one of the suitable options. 3 , 4 Yet the presence of Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; MET, metformin; OAD, oral antidiabetes drug; SU, sulfonylurea.
different patient characteristics, types of studies, types of combination therapies, and definitions of hypoglycaemia, to name just a few confounding factors, may confuse the issue. Further, the position statements of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) on management of hyperglycaemia in T2D emphasise the importance of tailoring therapy for adult patients with T2D, 3, 4 and state that patient factors such as age, gender, and body mass index (BMI) should be taken into account when making treatment decisions. The guidelines state that special care is required in prescribing and monitoring pharmacological treatment in older adults. 3, 4 Separately, previous studies have suggested that females with T2D are less likely to reach glycaemic targets and have a higher risk of hypoglycaemia with insulin therapy compared with males, suggesting that gender may play a role in tailoring therapy for individual patients. 5, 6 Previous studies have suggested also that BMI may affect the glycated haemoglobin A1c
(HbA1c) level achieved and the risk of hypoglycaemia in patients with T2D. 7, 8 Clear guidance is needed to assist physicians in weighing patient characteristics when initiating basal insulin.
The objective of this study was to analyse patient-level data, comparing standardised clinical outcomes in insulin-naïve patients with T2D for whom treatment involved the addition of insulin glargine 100 U/mL (Gla-100) to existing OADs according to these important variables: age, gender, BMI category, and type of concomitant OAD use.
| METHODS

| Study selection
To be eligible for inclusion in this analysis, studies had to be prospective, randomized, controlled treat-to-target trials (target fasting plasma glucose [FPG] level ≤100 mg/dL) with a duration of ≥24 weeks, for which safety population patient-level data were available for analysis. This last criterion, therefore, limited studies to those published by Sanofi. All Sanofi-sponsored studies fulfilling the inclusion criteria were included in the analysis. Inclusion criteria were:
treat-to-target with protocol-driven titration and an FPG target of <100 mg/dL, study duration ≥24 weeks, T2D patients receiving glargine in combination with sulfonylurea (SU), metformin (MET) or MET +SU, collection of sufficient data on hypoglycaemia. No imputation was used; only data that were captured within the visit window were included. Patients were insulin-naive adults with T2D, for whom Gla-100 was added to their current oral therapy. No data from patients requiring bolus insulin were used. Only bedtime glargine regimes were used for calculations. A total of 16 studies fulfilled all of the inclusion criteria (Table S1 ). 
| Statistical analyses
Standardised patient-level data were pooled from the identified studies.
Patient characteristics at baseline and week 24 were reported using descriptive statistics. 3 | RESULTS
| Patients
Overall, 3188 patients from 16 studies were included in this analysis.
Patient demographics and clinical characteristics are summarised here (full data for the subgroups are given in Table S2 ). In the overall population, 52.7% were male, mean age was 57.7 years, and T2D duration was 9.0 years. Mean weight at baseline was 86.0 kg and mean BMI was 30.5 kg/m 2 . Mean HbA1c at baseline was 8.7% and FPG 192.1 mg/dL. Gla-100 was added to MET in 644 patients, to SU in 920 patients, and to MET+SU in 1624 patients.
With regards to age at baseline (Table S2A ), 75.6% of patients were <65 years and 24.4% were ≥65 years. Younger patients had shorter mean duration of T2D, higher weight and BMI, and slightly higher HbA1c and FPG than older patients. The mean initial dose of Gla-100 was similar in both age groups.
Mean age, duration of T2D, and HbA1c were the same for males and females (Table S2B ). Mean FPG was slightly higher among males than females. The mean initial dose of Gla-100 was similar for both genders.
Of patients with BMI data available at baseline (n = 3187) (Table S2C) , BMI category was normal in 11.5%, was overweight in 38.1% and was obese in 50.4% of patients. Patients with a lower BMI had a longer duration of T2D. Baseline HbA1c levels were similar across all BMI categories, and FPG was highest in overweight patients; normal and obese patients had remarkably similar FPG.
Initial Gla-100 dose was highest among normal and lowest among obese patients.
| Efficacy
All analyses compared baseline with results at 24 weeks. In addition, separate analyses looked at patients by age, gender and BMI regardless of the type of OAD used, and by age, gender and BMI stratified by the type of OAD used.
In the overall study population, mean HbA1c decreased from 8.74% at baseline to 7.19% at week 24. Age (P = .003), male gender (P < .001) and baseline FPG (P = .008) were negatively related to HbA1c at endpoint. Baseline HbA1c (P < .001), diabetes duration (P < .001) and treatment with SU only (vs MET) (P = .007) were positively related to HbA1c at endpoint. Overall, 45.6% of patients reached the target HbA1c of <7.0%.
FPG decreased from 191.7 to 118.1 mg/dL. Age (P < .001) and initial insulin dose (P = .001) were negatively related to FPG at week 24, and baseline BMI (P = .002), use of SU only (P < .001) or MET +SU (P = .002) (vs MET) were positively related to endpoint FPG.
Overall, 34.7% of patients achieved the target FPG of ≤100 mg/dL.
Subanalysis of patients by age revealed that younger patients had a slightly greater mean reduction in HbA1c compared with older patients, regardless of concomitant OAD ( Figure 1A ), whereas age had little impact on mean reductions in FPG at week 24 ( Figure 1B ).
Mean reductions in FPG for patients using SU only or MET+SU did not differ by age. However, among patients using MET only, younger patients had greater mean reductions in FPG than did those aged ≥65 years ( Figure 1B) . The proportion of patients in varying groups reaching HbA1c <7% is depicted in Table S3 .
Subanalysis by gender revealed mean reductions in HbA1c from baseline to week 24 that were lower in females than in males this pattern was seen regardless of the concomitant OAD ( Figure S1 ).
Mean changes in FPG from baseline to week 24 differed according to BMI category, with larger reductions observed in patients in the normal category as compared to the overweight and obese categories; consequently, FPG levels at week 24 were lower in patients in the normal category and higher in patients in the overweight and obese categories (109.3 vs 116.6 vs 121.2 mg/dL, respectively).
| Hypoglycaemia
Age had little effect on incidence ( Figure 3A ) and event rates (Figure 3B) of overall, nocturnal and severe hypoglycaemia, which were comparable in younger and older patients. Age (P = .02), baseline BMI (P < .001) and HbA1c (P = .003) were negatively associated, and duration of disease (P = .004), initial insulin dose (P < .001), SU only (P = .002) and MET+SU (P = .001) (vs MET) were positively associated with overall hypoglycaemia incidence. Age (P = .023), gender (male vs female) (P = .012), baseline BMI (P < .001) and baseline HbA1c (P = .002) were negatively associated, and duration of diabetes (P = .009), initial insulin dose (P < .001), SU only (P < .001) and MET+SU (P < .001) (vs MET) were positively associated with the event rate of overall hypoglycaemia.
Overall hypoglycaemia incidence was similar in both age groups, regardless of concomitant OAD. The incidence of nocturnal hypoglycaemia was higher in older patients using SU only and in younger patients using MET+SU. The incidence of severe hypoglycaemia was mostly similar between younger and older patients regardless of OAD group, except that the incidence was higher among younger patients using MET only. The event rate for overall and nocturnal hypoglycaemia was highest among patients using MET+SU regardless of age, followed by patients using SU only, with a slightly higher rate in older as compared to younger patients. In subanalysis by gender, the incidence and event rates of overall and nocturnal severe hypoglycaemia and the event rates of overall, nocturnal and nocturnal severe hypoglycaemia were significantly higher in females than in males (Figure 4 ). This pattern generally was repeated when analysed by concomitant OAD. In all cases, the incidence of hypoglycaemia was at least slightly higher in females than in In subanalysis by BMI category, the hypoglycaemia incidence and event rates were highest in patients in the normal BMI category, irrespective of the concomitant OAD ( Figure 5 ). When patients were analysed by concomitant OAD, overall hypoglycaemia incidence was highest in those taking MET+SU regardless of BMI category; hypoglycaemia incidences in patients in the normal BMI category taking MET only or SU only were similar to one another, but in each case, it was higher than that in patients in the overweight and obese BMI categories. Of note, the incidence of overall hypoglycaemia among patients in the obese BMI category was higher in those taking SU only (33.43%) than in those taking MET only (27.20%). Overall hypoglycaemia event rates were higher in patients in the normal BMI category taking SU only (9.67 events/patient-year) or MET+SU (10.03 events/patient-year) vs MET only (6.16 events/patient-year). For patients in the overweight and obese BMI categories, hypoglycaemia event rates were highest in patients taking MET+SU, followed by those taking SU only, and was lowest in those taking MET only.
| Body weight and isulin dose
In the overall patient cohort, mean body weight increased from 85.9 to 87.8 kg. Age (P < .001) and baseline BMI (P = 0.028) were negatively associated, and baseline HbA1c (P < .001), baseline FPG and initial dose (P < .001, each), SU only (P < .001) and MET+SU (P = .006) (vs MET) were positively associated with weight at endpoint. Mean insulin dose increased from 0.16 to 0.43 IU/kg. Age and duration (P < .001, each) and MET+SU (P = 0.001) (vs MET) were negatively associated, and baseline BMI and FPG (P < .001, each), and baseline HbA1c (P = .002) were positively associated with insulin dose at endpoint (Table S4) 
| DISCUSSION
This study was an analysis of pooled, standardised data from randomized, controlled treat-to-target trials with a duration of ≥24 weeks, conducted in insulin-naïve adults with T2D for whom Gla-100 was added to their current OAD therapy. The analysis used data from 16 different studies involving more than 3100 patients. The fact that Gla-100 is widely available and extensively used means that the findings of this analysis are of interest to a wide global audience. This analysis provides data on standardised clinical outcomes in patients initiating basal insulin therapy with Gla-100, taking into account the main confounders that have been present in clinical studies, and presenting a more detailed picture with regard to age, gender, and BMI.
In the overall study population, certain trends were revealed.
First, addition of Gla-100 to any OAD led to significant reductions in HbA1c and FPG, allowing 45.6% of patients to achieve a target FIGURE 5 Hypoglycaemia event rates (overall and nocturnal with PG <70 mg/dL), stratified by BMI category and OAD use. BMI, body mass index; MET, metformin; OAD, oral antidiabetes drug; SU, sulfonylurea HbA1c <7.0%. Second, baseline factors with a significant impact on HbA1c at endpoint were age, gender, and baseline FPG, which had a negative association with respect to the percentage of the specific group reaching HbA1c targets. Baseline HbA1c, diabetes duration, and treatment with SU only vs MET had a positive association only in regards to reaching HbA1c targets. Third, although just over 40% of patients experienced some hypoglycaemia, severe hypoglycaemia occurred much less often in 1.99% of patients. Fourth, mean body weight increases with addition of Gla-100 were modest (<2 kg) in the overall cohort. Adding Gla-100 to MET only resulted in the highest percentage of patients achieving HbA1c <7.0%, mitigated weight increase, and was associated with a low incidence of hypoglycaemia.
In subanalysis by age, Gla-100 use in older patients with T2D
resulted in clinical outcomes similar to those in younger patients, but at lower insulin doses and with less weight gain. Severe hypoglycaemia was rare in both age groups and was not increased in older patients. Patients at any age were most likely to achieve HbA1c < 7.0% without hypoglycaemia when adding Gla-100 to background MET only.
Subanalysis by gender revealed that female patients with T2D
are less likely to reach glycaemic targets and have a higher risk of hypoglycaemia when adding basal insulin therapy to current OADs, particularly when adding Gla-100 to SU only or MET+SU. This finding supports previous data and suggests that women are more difficult to treat, in terms of efficacy and safety, compared with men, and that gender differences should be considered when tailoring treatment for individual patients. 5, 6 The gender difference was consistent, possibly indicating a biological difference between males and females. Weight gain was low and similar for males and females, suggesting that weight gain is not an issue of particular concern when initiating Gla-100 in either gender. In both males and females, use of concomitant SU was associated with greater weight gain than use of concomitant MET alone.
Subanalysis by BMI category revealed that overweight and obese patients are more likely to reach HbA1c targets with higher insulin doses and with less hypoglycaemia than patients in the normal BMI category. This is in line with previous findings that low BMI is a risk factor for hypoglycaemia. 25 Weight gain was lower in the overweight and obese BMI categories than in the normal BMI category, suggesting that weight gain is not of particular concern among patients with a high BMI who are initiating insulin treatment; weight gain is more likely to occur in patients with a normal BMI. In the subanalysis by BMI category and OAD use, patients across all BMI categories who initiated basal insulin on background SU had lower HbA1c reduction, were less likely to achieve HbA1c <7.0%, and had greater rates of hypoglycaemia. Background OAD had an impact on weight gain across BMI categories and tended to be highest among patients adding insulin to SU.
| What this study contributes
Many patients with T2D require treatment with insulin at some point as disease progresses, yet there is limited information available to assist clinicians in predicting response to basal insulin therapy. A PubMed search of the terms "predictors of response," "basal insulin therapy" and "gender or BMI or age or OAD" yielded only seven articles, three of which were unrelated to diabetes care. The other four studies were observational in design and did not examine the effect of background OAD therapy on insulin response [26] [27] [28] [29] and two studies included treatment with multiple insulin types. 26, 28 There is no other analysis of pooled patient-level data from clinical trials measuring response at the same time point, using the same insulin type.
Our results are broadly consistent with some, although not all, findings from other investigations. One study reported higher HbA1c among females after 1 to 4 years of insulin therapy, 28 whereas another reported that gender did not predict response to insulin therapy. 26 However, our analysis which demonstrated that women were less likely to achieve HbA1c target and more likely to experience hypoglycaemia is supported by the results of only 2 pooled analyses that examined only the effect of gender on glycaemic control and hypoglycaemia. 5, 6 Consistent with our study, a survey of health care professionals (n=1333) reported that lower BMI predicted worse glycaemic control. 8 Conversely, two observational studies found that achieving a glycaemic goal was more likely in leaner patients, 26, 29 while another linked higher BMI to higher HbA1c. 28 Unlike our findings, four investigations reported a significant effect of age on insulin response. 8, 26, 28, 29 Older age was associated with achievement of glycaemic target with basal insulin at 6 months 29 and at 12 months, 26 while two studies reported an association between younger age and worse control.
8,28
| Understanding hypoglycaemia
The association of hypoglycaemia with insulin use remains one of the most important issues in T2D management. 30 To enable informed decisions about therapy choices for patients with T2D, it is important that clinicians understand how different patient factors and existing background medications affect the risk of hypoglycaemia associated with initiation of basal insulin therapy. 31 
| Directions for future research
This analysis indicates that female, as compared to male patients, and those with normal BMI, as compared to overweight or obese individuals, were less likely to achieve HbA1c targets and more likely to develop hypoglycaemia when Gla-100 was added to background OAD therapy. Whether gender and body weight are associated with response to addition of other basal insulin formulations, or other types of therapy, to background treatment including MET and/or SU is a question that needs to be addressed in future studies.
| Strengths and limitations
The number of patients included in this analysis, as well as inclusion of patients aged ≥65 years, can be considered a strength and lends validity to its conclusions. One of the other strengths is that the definition of hypoglycaemia was consistent. Nonetheless, these patient data were drawn exclusively from clinical trial populations and, as such, were restricted to individuals who met the inclusion criteria for these studies. Additionally, we analysed only patients receiving concomitant MET, SU, or combined MET+SU, whereas, currently, many patients with T2D receive treatment with other classes of oral agents or injected glucagon-like peptide-1 (GLP-1) receptor agonists.
The trials included in this analysis utilised different doses of MET and SU, and different regimens of Gla-100 administration (morning or bedtime). In some studies, patients received a thiazolidinedione or other antidiabetes medications in addition to MET and/or SU (Table S1 ). Patients in the trials reflected a diversity of populations, so that patient ethnicity and local clinical practice could have influenced results. Older adult participants who were recruited into the trials may have fewer comorbidities than those seen in clinical practice, including a lower incidence of cognitive dysfunction. Comorbidities and dementia may affect rates of hypoglycaemia in older adults. 32, 33 Finally, our follow-up period in this analysis was limited to 24 weeks, and thus could not account for differences in glycaemic control or hypoglycaemia that occurred in longer-term use of Gla-100 and OADs.
| Conclusions
The key message from these analyses is, that when tailoring therapy for individual patients with T2D, it should be taken into account that women and patients within the normal BMI range are less likely to reach glycaemic targets and have a higher risk of hypoglycaemia when adding Gla-100 to current OAD therapy. Initiation of insulin therapy and ongoing management of these patients, therefore, should be carefully monitored. Age is less likely to be important, although factors concerning individual patients (e.g. polypharmacy, comorbidity, and advanced age) should be taken into account. A patient's background OAD is also relevant, as use of concomitant SU was associated with more weight gain and hypoglycaemia, regardless of patient age, gender, or BMI category, than was use of concomitant MET. This suggests that physicians should consider discontinuing SU therapy when initiating a Gla-100 regimen.
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